Florence, April 07, 2026
From April 16 to 18, 2026, Hospitex will take part in Expomed Eurasia in Istanbul, joining Aliko Scientific at the Italian Trade Agency pavilion – Hall 8, Stand 8/840D.
The event will see the presence of Francesco Trisolini, CEO of Hospitex, who will meet partners and stakeholders to discuss new collaboration opportunities and the evolving role of cytology in cancer diagnostics.
Precision cytology as a key driver for early diagnosis in Asia
Across many Asian and Eurasian countries, healthcare systems are facing increasing pressure to improve early cancer detection while maintaining efficiency and cost sustainability. In this context, precision cytology represents a fundamental diagnostic pillar.
Hospitex solutions are designed to deliver:
- Standardized and reproducible sample preparation, ensuring high diagnostic quality
- Scalable workflows, adaptable to both centralized and decentralized laboratory models
- Integration with molecular diagnostics, enabling a seamless transition from morphology to advanced analysis
This approach allows laboratories to maximize the diagnostic value of each sample, supporting early detection strategies and improving patient outcomes, particularly in regions where access to advanced diagnostics is still developing.
As part of the Aliko Scientific ecosystem, Hospitex contributes to a fully integrated diagnostic pathway, where cytology plays a central role in enabling efficient, high-quality screening and diagnosis processes.
Building new partnerships in a high-growth region
Participation in Expomed Eurasia reflects Hospitex’s commitment to expanding its international distributor network and building long-term partnerships with local players. After the successful meetings in Dubai, the company is continuing its dialogue with selected partners interested in introducing innovative cytology technologies into their markets.
